Tirzepatide

Tirzepatide is a dual GIP (Glucose-dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-Like Peptide-1) receptor agonist. In research settings, it is noted for being more potent than Semaglutide because it hits two hormonal pathways instead of one, leading to superior blood glucose management and weight loss with potentially fewer side effects for some individuals.
________________________________________

1. Reconstitution & Dosage
Tirzepatide is typically found in 5mg, 10mg, or 15mg lyophilized vials. Because the maintenance doses can get quite high, the math for reconstitution is critical.

• Reconstitution: Add 2ml of Bacteriostatic Water to a 10mg vial.
• The Concentration: This creates 5mg per 1ml.
• Syringe Measurement (U-100 Insulin Syringe):
o 50 units (0.50ml) = 2.5mg (Starter Dose)
o 100 units (1.0ml) = 5mg
________________________________________

2. The Escalation Protocol
Like Semaglutide, Tirzepatide requires a "Start Low, Go Slow" approach to minimize gastrointestinal side effects.

Weeks Dosage Frequency
Weeks 1–4 2.5mg Once Weekly
Weeks 5–8 5.0mg Once Weekly
Weeks 9–12 7.5mg Once Weekly
Weeks 13–16 10.0mg Once Weekly

Maintenance: Doses can continue to escalate by 2.5mg every 4 weeks up to a maximum of 15mg, though many researchers find a "sweet spot" at 5mg or 7.5mg and stay there as long as progress continues.
________________________________________

3. Administration & Timing

• Subcutaneous (SubQ): Injected into the fatty tissue of the abdomen, thigh, or upper arm.

• Timing: Administered once weekly at any time of day.

• Flexibility: If a dose is missed, it can be administered within 4 days (96 hours) of the missed dose. If more than 4 days have passed, the researcher usually skips that dose and resumes on the next scheduled day.
________________________________________

4. Potential Side Effects
• GI Distress: Nausea, diarrhea, and decreased appetite are common.
• Injection Site Pain: Because Tirzepatide is a larger molecule than some other peptides, some report mild stinging or "itchy" welts at the site.
• Heart Rate: A slight increase in resting heart rate (2–4 bpm) is sometimes observed in research.
• Fatigue: Often reported during the first 48 hours after a dose increase.
________________________________________

5. Pro-Tips for Research Success
• Protein First: To prevent "muscle wasting," research subjects are often placed on a high-protein diet (1.2g to 1.5g per kg of body weight).
• Electrolyte Loading: Tirzepatide can cause rapid water weight loss in the first two weeks; adding electrolytes to water helps prevent the "faint" feeling sometimes associated with the drug.
• Cold Storage: Once mixed, Tirzepatide is highly sensitive. It must be refrigerated and kept out of direct light.
________________________________________

Quick Checklist for a 10mg Vial:
• At 2.5mg/week: One vial lasts 4 weeks.
• At 5.0mg/week: One vial lasts 2 weeks.
• Supplies: 31g, 5/16" (8mm) insulin syringes.